GlassScriptPhysician profile
Andrew Hart
NPI 1275680142
$2,195.08
in general payments reported to CMS, 2019-2025
41 companies · $474 in 2025
The $474 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $167 · 2021: $112 · 2022: $113 · 2023: $372 · 2024: $817 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,636.13 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $329.43 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $193.82 | 2023-2025 | |
| Pfizer INC. | $166.31 | 2023-2025 | |
| Daiichi Sankyo INC. | $131.20 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Astellas Pharma US INC | $118.74 | 2024-2025 | Vyloy, Xtandi, Cresemba |
| Genmab U.S., INC. | $116.55 | 2024 | Epkinly |
| Astrazeneca Pharmaceuticals LP | $100.75 | 2020-2025 | Lynparza, Enhertu |
| Emd Serono, INC. | $100.00 | 2020 | |
| Merck Sharp & Dohme LLC | $76.20 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $63.47 | 2022-2023 | Padcev |
| Tempus Ai, INC | $58.03 | 2024 | |
| Foundation Medicine, INC. | $55.88 | 2019-2020 | |
| Amgen INC. | $49.89 | 2019-2022 | |
| Glaxosmithkline, LLC. | $47.83 | 2021-2025 | Ojjaara |
| Incyte Corporation | $39.08 | 2023-2024 | Jakafi |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.